Management of osteoporosis in the aging male: Focus on zoledronic acid

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Detection, and TherapyOsteoporosis prevention, diagnosis, and therapyJAMA200128578579511176917
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation Advocacy News and UpdatesThe state of osteoporosis and low bone mass in the US. 2009 Cited 2009 Feb 18. Available from: http://www.nof.org/advocacy/prevalence/index.htm
   Google Scholar
• JonesGNguyenTSambrookPNKellyPJGilbertCEismanJASymptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES)Osteoporosis Int19944277282
   PubMed Web of Science ®Google Scholar
• WinnerSJMorganCAEvansJGPerimenopausal risk of falling and incidence of distal forearm fractureBMJ19892986686148614882503081
   PubMed Web of Science ®Google Scholar
• Office of the Surgeon GeneralThe burden of bone diseaseBone health and osteoporosis: A report of the Surgeon General2004 Cited 2009 Jan 31. Available from: http://www.surgeongeneral.gov/library/bonehealth/chapter_5.html
   Google Scholar
• LeibsonCLTostesonANGabrielSERansomJEMeltonLJMortality, disability, and nursing home use for persons with and without hip fracture: a population-based studyJ Am Geriatr Soc200250101644165012366617
   PubMed Web of Science ®Google Scholar
• CenterJRNguyenTVSchneiderDMortality after all major types of osteoporotic fractures in men and women: an observational studyLancet199976235242
   Google Scholar
• MagazinerJFredmanLHawkesWChanges in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling agedAm J Epidemiol2003157111023103112777366
   PubMed Web of Science ®Google Scholar
• ChrischillesEAButlerCDDavisCSWallaceRBA model of lifetime osteoporosis impactArch Intern Med199115110202620321929691
   PubMedGoogle Scholar
• TostesonANOrwollESEconomic impact of fracturesOsteoporosis in men: The effects of gender on skeletal healthSan DiegoAcademic Press19991527
   Google Scholar
• HasseriusRKarlssonMKJonssonBLong-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly: a 12- and 22-year follow-up of 257 patientsCalcif Tissue Int20057623524215812579
   PubMed Web of Science ®Google Scholar
• LewisCEEwingSKTaylorBCfor the Osteoporotic Fractures in Men (MrOS) Study Research GroupPredictors of non-spine fracture in elderly men: the MrOS studyJ Bone Miner Res200722221121917059373
   PubMed Web of Science ®Google Scholar
• NguyenTVEismanJAKellyPARisk factors for osteoporotic fractures in elderly menAm J Epidemiol19961442552638686694
   PubMed Web of Science ®Google Scholar
• GruntmanisUMale osteoporosis: deadly, but ignoredAm J Med Sci20073332859217301586
   PubMed Web of Science ®Google Scholar
• KelepourisNHarperKDGannonFKaplanFSHaddadJGSevere osteoporosis in menAnn Intern Med199512364524607639446
   PubMed Web of Science ®Google Scholar
• OrwollESKleinRFOsteoporosis in menEndocr Rev1995161871167758434
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborating Centre for Metabolic Bone DiseasesFRAX^® WHO Fracture Risk Assessment ToolSheffield, UKWorld Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK2009 Cited 2009 Feb 13. Available from: http://www.shef.ac.uk/FRAX/index.htm
   Google Scholar
• KhoslaSAminSOrwollEOsteoporosis in menEndocr Rev200829444146418451258
   PubMed Web of Science ®Google Scholar
• EbelingPROsteoporosis in menN Engl J Med20083581474148218385499
   PubMed Web of Science ®Google Scholar
• SherringtonCWhitneyJCLordSRHerbertRDCummingRGCloseJCEffective exercise for the prevention of falls: a systematic review and meta-analysisJ Am Geriatr Soc200856122234224319093923
   PubMed Web of Science ®Google Scholar
• Martyn-St JamesMCarrollSHigh-intensity resistance training and postmenopausal bone loss: a meta-analysisOsteoporos Int20061781225124016823548
   PubMed Web of Science ®Google Scholar
• LarsenERMosekildeLFoldspangAVitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention studyJ Bone Miner Res200419337037815040824
   PubMed Web of Science ®Google Scholar
• TrivediDPDollRKhawKTEffect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trialBMJ2003326738746912609940
   PubMed Web of Science ®Google Scholar
• Dawson-HughesBHarrisSSKrallEADallalGEEffect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or olderN Engl J Med1997337106706769278463
   PubMed Web of Science ®Google Scholar
• GrantAMAvenellACampbellMKfor RECORD Trial GroupOral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trialLancet200536594711621162815885294
   PubMed Web of Science ®Google Scholar
• National Osteoporosis FoundationClinician’s guide to prevention and treatment of osteoporosis2009 Cited 2009 Feb 18. Available from: http://www.nof.org/professionals/cliniciansguide_form.asp
   Google Scholar
• TrovasGPLyritisGPGalanosARaptouPConstantelouEA randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markersJ Bone Miner Res200217352152711874243
   PubMed Web of Science ®Google Scholar
• TothECsuporEMeszarosSThe effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures – an open label studyBone2005361475115664001
   PubMed Web of Science ®Google Scholar
• WangCCunninghamGDobsALong-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal menJ Clin Endocrinol Metab20048952085209815126525
   PubMed Web of Science ®Google Scholar
• SnyderPJPeacheyHBerlinJAEffects of testosterone replacement in hypogonadal menJ Clin Endocrinol Metab20008582670267710946864
   PubMed Web of Science ®Google Scholar
• SnyderPJPeacheyHBerlinJAEffect of testosterone treatment on bone mineral density in men over 65 years of ageJ Clin Endocrinol Metab19998461966197210372695
   PubMed Web of Science ®Google Scholar
• KatznelsonLFinkelsteinJSSchoenfeldDARosenthalDIAndersonEJKlibanskiAIncrease in bone density and lean body mass during testosterone administration in men with acquired hypogonadismJ Clin Endocrinol Metab19968112435843658954042
   PubMed Web of Science ®Google Scholar
• AndersonFHFrancisRMPeastonRTWastellHJAndrogen supplementation in eugonadal men with osteoporosis: effects of six months’ treatment on markers of bone formation and resorptionJ Bone Miner Res19971234724789076591
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSHayesAHunzelmanJLWylandJJLeeHNeerRMThe effects of parathyroid hormone, alendronate, or both in men with osteoporosisN Engl J Med20033491216122614500805
   PubMed Web of Science ®Google Scholar
• SaagKGShaneEBoonenSTeriparatide or alendronate in glucocorticoid-induced osteoporosisN Engl J Med20073572028203918003959
   PubMed Web of Science ®Google Scholar
• RussellRGBisphosphonates: from bench to bedsideAnn NY Acad Sci2006106836740116831938
   PubMed Web of Science ®Google Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
   PubMed Web of Science ®Google Scholar
• SmithMRBisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancerDrugs Aging200320317518312578398
   PubMed Web of Science ®Google Scholar
• DrakeMTClarkeBLKhoslaSBisphosphonates: mechanism of action and role in clinical practiceMayo Clin Proc20088391032104518775204
   PubMed Web of Science ®Google Scholar
• ReidIRBisphosphonates: new indications and methods of administrationCurr Opin Rheumatol200315445846312819475
   PubMed Web of Science ®Google Scholar
• HallARho GTPases and the actin cytoskeletonScience199827953505095149438836
   PubMed Web of Science ®Google Scholar
• WeinsteinRSRobersonPKManolagasSCGiant osteoclast formation and long-term oral bisphosphonate therapyN Engl J Med2009360536219118304
   PubMed Web of Science ®Google Scholar
• RyanPJBlakeGMDavieMHaddawayMGibsonTFogelmanIIntermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safetyOsteoporos Int200011217117610793877
   PubMed Web of Science ®Google Scholar
• BrumsenCPapapoulosSELipsPDaily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extensionJ Bone Miner Res20021761057106412054161
   PubMed Web of Science ®Google Scholar
• BoutsenYJamartJEsselinckxWDevogelaerJPPrimary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium aloneJ Bone Miner Res200116110411211149473
   PubMed Web of Science ®Google Scholar
• HoYVFraumanAGThomsonWSeemanEEffects of alendronate on bone density in men with primary and secondary osteoporosisOsteoporos Int20001129810110793867
   PubMed Web of Science ®Google Scholar
• OrwollEEttingerMWeissSAlendronate for the treatment of osteoporosis in menN Engl J Med200034360461010979796
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFaberHIbachKAlendronate treatment of established primary osteoporosis in men: 2-year results of a prospective, comparative, two-arm studyRheumatol Int20042411011313680141
   PubMed Web of Science ®Google Scholar
• SawkaAMPapaioannouAAdachiJDGafniAHanleyDAThabaneLDoes alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in womenBMC Musculoskelet Disord200563916008835
   PubMed Web of Science ®Google Scholar
• RingeJDFaberHFarahmandPDorstAEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year studyRheumatol Int20062642743116001181
   PubMed Web of Science ®Google Scholar
• BoonenSOrwollESWenderothDStonerKJEusebioRDelmasPDOnce-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter studyJ Bone Miner Res20092471972519049326
   PubMed Web of Science ®Google Scholar
• ReidDMAdamiSDevogelaerJ-PChinesAARisedronate increases done density and reduces vertebral fracture risk within one year in men on corticosteroid therapyCalcif Tissue Int20016924224711730260
   PubMed Web of Science ®Google Scholar
• SatoYIwamotoJKanokoTSatohKRisedronate sodium therapy for prevention of hip fracture in men 65 years or older after strokeArch Intern Med20051651743174816087822
   PubMed Web of Science ®Google Scholar
• LealAMFossNTEndocrine dysfunction in leprosyEur J Clin Microbiol Infect Dis2009281718629555
   PubMed Web of Science ®Google Scholar
• IshikawaSIshikawaAYohKTanakaHFujiwaraMOsteoporosis in male and female leprosy patientsCalcif Tissue Int1999641441479914322
   PubMed Web of Science ®Google Scholar
• KanajiAHigashiMNamisatoMNishioMAndoKYamadaHEffects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosyLepr Rev20067714715316895071
   PubMed Web of Science ®Google Scholar
• ParfittJRDrimanDKPathological effects of drugs on the gastrointestinal tract: a reviewHum Pathol20073852753617367604
   PubMed Web of Science ®Google Scholar
• WysowskiDKReports of esophageal cancer with oral bisphosphonate useN Engl J Med20093601899019118315
   PubMed Web of Science ®Google Scholar
• MacLeanCNewberrySMaglioneMSystematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosisAnn Intern Med200814819721318087050
   PubMed Web of Science ®Google Scholar
• TostesonANGroveMRHammondCSEarly discontinuation of treatment for osteoporosisAm J Med2003115320921612947959
   PubMed Web of Science ®Google Scholar
• PapaioannouAKennedyCCDolovichLLauEAdachiJDPatient adherence to osteoporosis medications: problems, consequences and management strategiesDrugs Aging2007241375517233546
   PubMed Web of Science ®Google Scholar
• YoodRAEmaniSReedJILewisBECharpentierMLydickECompliance with pharmacologic therapy for osteoporosisOsteoporos Int20031496596814504697
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• HamiltonBMcCoyKTaggartHTolerability and compliance with risedronate in clinical practiceOsteoporos Int20031425926212730745
   PubMed Web of Science ®Google Scholar
• SolomonDHAvornJKatzJNCompliance with osteoporosis medicationsArch Intern Med20051652414241916287772
   PubMed Web of Science ®Google Scholar
• LamyOSandiniLPacheIFatioSBurnandJBurckhardtPIntravenous ibandronate in men with osteoporosis: an open pilot study over 2 yearsJ Endocrinol Invest200326872873214669826
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFaberHIbachKSorensonFIntermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative studyOsteoporos Int20031480180714610641
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxy-apatiteBone20063861762716046206
   PubMed Web of Science ®Google Scholar
• LylesKWColón-EmericCSMagazinerJSfor the HORI -ZON Recurrent Fracture TrialZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med20073571799180917878149
   PubMed Web of Science ®Google Scholar
• Colón-EmericCMesenbrinkPLylesKPotential mediators of the reduction in mortality with zoledronic acid after hip fracture [abstract]Presented at the American Society for Bone Mineral Research meetingSept 13, 2008
   Google Scholar
• Novartis PharmaceuticalsReclast prescribing information32009 Cited 2009 May 18. Available from: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=8476
   Google Scholar
• PooleKELoveridgeNRoseCMWarburtonEAReeveJA single infusion of zoledronate prevents bone loss after strokeStroke2007381519152517395868
   PubMed Web of Science ®Google Scholar
• BrownTTQaqishRBAntiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewAIDS200620172165217417086056
   PubMed Web of Science ®Google Scholar
• TriantVABrownTTLeeHGrinspoonSKFracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare systemJ Clin Endocrinol Metab20089393499350418593764
   PubMed Web of Science ®Google Scholar
• BollandMJGreyABHorneAMAnnual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trialJ Clin Endocrinol Metab2007921283128817227801
   PubMed Web of Science ®Google Scholar
• ReidIRBrownJPBurckhardtPIntravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med200234665366111870242
   PubMed Web of Science ®Google Scholar
• BorbaVZPaz-FilhoGKulakCASeibelMJBilezikianJPBone turnover 18 months after a single intravenous dose of zoledronic acidInt J Clin Pract20076161058106217504370
   PubMed Web of Science ®Google Scholar
• BollandMJGreyABHorneAMEffects of intravenous zoledronate on bone turnover and BMD persist for at least 24 monthsJ Bone Miner Res2008231304130818627266
   PubMed Web of Science ®Google Scholar
• BrownJEEllisSPLesterJEProlonged efficacy of a single dose of the bisphosphonate zoledronic acidClin Cancer Res200713185406541017875770
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSLederBZBurnettSMEffects of teriparatide, alendronate, or both on bone turnover in osteoporotic menJ Clin Endocrinol Metab20069182882288716684825
   PubMed Web of Science ®Google Scholar
• WelchBJDenkeMAKermaniAAdams-HuetBGazmenNMGruntmanisUComparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral densityJ Invest Med2007554168173
   Web of Science ®Google Scholar
• GreenspanSLCoatesPSereikaSMNelsonJBTrumpDLResnickNMBone loss after initiation of androgen deprivation therapy in patients with prostate cancerJ Clin Endocrinol Metab2005906410641716189261
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoY-FFreemanJLGoodwinJSRisk of fracture after androgen-deprivation for prostate cancerN Engl J Med200535215416415647578
   PubMed Web of Science ®Google Scholar
• SmithMRMcGovernFJZietmanALPamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancerN Engl J Med200134594895511575286
   PubMed Web of Science ®Google Scholar
• GreenspanSLNelsonJBTrumpDLSkeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapyJ Clin Oncol2008264426443418802155
   PubMed Web of Science ®Google Scholar
• RyanCWHuoDDemersLMBeerTMLacernaLVfor the Zometa US05 InvestigatorsZoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancerJ Urol200617697297816890673
   PubMed Web of Science ®Google Scholar
• SmithMREasthamJGleasonDMShashaDTchekmedyianSZinnerNRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol20031692008201212771706
   PubMed Web of Science ®Google Scholar
• MichaelsonMDKaufmanDSLeeHRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist–induced bone loss in men with prostate cancerJ Clin Oncol2007251038104217369566
   PubMed Web of Science ®Google Scholar
• RyanCWHuoDBylowKSuppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acidBJU Int2007100707517552955
   PubMed Web of Science ®Google Scholar
• DoranPMRiggsBLAtkinsonEJKhoslaSEffects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly menJ Bone Miner Res200116112118212511697809
   PubMed Web of Science ®Google Scholar
• SmithMRFallonMALeeHFinkelsteinJSRaloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trialJ Clin Endocrinol Metab2004893841384615292315
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRfor the HORIZON Pivotal Fracture TrialFracture trial once-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med20073561809182217476007
   PubMed Web of Science ®Google Scholar
• FDA MedwatchBisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)Washington DCUS Food and Drug Administration Updated 2008 Jan 7. Cited 2008 Dec 12. Available from: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Bisphosphonates
   Google Scholar
• KhoslaSBurrDCauleyJBisphosphonate-associated osteone-crosis of the jaw: report of a task force of the american society for bone and mineral researchJ Bone Miner Res2007221479149117663640
   PubMed Web of Science ®Google Scholar
• BoonyapakornTSchirmerIReichartPASturmIMassenkeilGBisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignanciesOral Oncol200844985786918282788
   PubMed Web of Science ®Google Scholar
• HeckbertSRLiGCummingsSRSmithNLPsatyBMUse of alen-dronate and risk of incident atrial fibrillation in womenArch Intern Med2008168882683118443257
   PubMedGoogle Scholar
• S⊘rensenHTChristensenSMehnertFUse of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ200833681381618334527
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationUpdate of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates Washington DC: US Food and Drug Administration Updated 2008 Nov 12. Cited 2009 Apr 22. Available from: http://www.fda.gov/CDER/drug/early_comm/bisphosphonates_update_200811.htm
   Google Scholar